The firm reported Q4 2014 revenues of $36.8 million, up from $32.7 million in Q4 2013, but falling short of analysts' average estimate of $41.9 million.
The partners will select and enroll patients with metastatic castration-resistant prostate cancer for a targeted Phase II trial for irofulven.
The company was founded in 2002 with a whole-genome mapping technology and more recently moved into the microbial genetics space.
Pfizer Canada will provide a grant and technical support to the National Access Project for genomic cancer testing.
The results also suggest the cfDNA assay has high sensitivity and 100 percent specificity, comparable to other technologies being developed for liquid biopsy testing.
In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.
A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.
Researchers report that paternally inherited genes are more likely to be expressed in mice.
In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.